Cancer of Unknown Primary Site
15
1
2
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
Trial of Pembrolizumab in Cancer of Unknown Primary
Sintilimab in Cancer of Unknown Primary
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
18F-FAPI PET in Cancers of Unknown Primary Site
The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP)
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary
Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Nivolumab/Ipilimumab in Second Line CUP-syndrome